Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma

Laryngoscope

Volumn 120, Issue 12, 2010, Pages 2456-2459

  Amin, Shivan H ^a   Tibes, Raoul ^b   Kim, Ji Eon ^a   Hybarger, C Patrick ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

basal cell carcinoma; GDC 0449; hedgehog antagonist; unresectable

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; GDC 0449; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CASE REPORT; CLINICAL TRIAL; DRUG EFFICACY; DYSGEUSIA; FEMALE; HAIR LOSS; HUMAN; MALE; METASTASIS; MUSCLE CRAMP; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ADULT; ANILIDES; BIOPSY; CARCINOMA, BASAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78649647341     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.21145     Document Type: Article

References (13)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146: 283-287.
2. Ming JE, Roessler E, Muenke M., Human developmental disorders and the Sonic hedgehog pathway. Mol Med Today 1998; 4: 343-349.
3. Sanchez-Camacho C, Rodriguez J, Ruiz JM, Trousse F, Bovolenta P., Morphogens as growth cone signalling molecules. Brain Res Brain Res Rev 2005; 49: 242-252.
4. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinoma. Nat Genet 1996; 14: 78-81.
5. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009, 361: 1173-1178.
6. Tang JY, So PL, Epstein EH Jr., Novel hedgehog pathway targets against basal cell carcinoma. Toxic App Pharm 2007; 224: 257-264.
7. Garber K., Hedgehog drugs begin to show results. J Natl Cancer Inst 2008; 100: 692-697.
8. Williams JA., Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. Drug News Persp 2003; 16: 657-662.
9. Athar M, Tang X, Lee JL, Kopelovich L, Kim AL., Hedgehog signalling in skin development and cancer. Exp Derm 2006; 15: 667-677.
10. Roop D, Toftgard R., Hedgehog in wnterland. Nature Gen 2008; 40: 1040-1041.
11. Zhang Y, Laterra J, Pomper MG., Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia 2009; 11: 96-101.
12. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med 2009; 361: 1162-1172.
13. Epstein EH., Basal cell carcinomas: attack of the hedgehog. Nature Rev 2008; 8: 743-754.